Skip to main content

Table 2 Dose-limiting toxicities in part I, phase A (DLT population)

From: Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

Events No. of patients (%)
  LD 5-FU (n = 7) HD 5-FU (n = 16)
No. patients with any event 0 (0) 2 (13)
Leucopenia or neutropenia grade 4 0 1 (6)
Occurrence of any drug-related AE that required treatment interruption within the first six weeks 0 1 (6)*
  1. LD = low-dose; HD = high-dose; AE = adverse event. Seven patients were recruited in the low-dose 5-FU arm due to an overlap in the enrolment of two patients.*Anaphylactic reaction.